Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Phase II Clinical Trials as Topic. Found 9 abstracts

Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espie M, Benchimol G, Laas E, Lae M, Asselain B, Aouchiche B, Edelman M, Reyal F. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. J Clin Oncol. 2019 Mar 10;37(8):624-35.   PMCID: PMC6804843
Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O. 2019 Mar;17(3):176-83.
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb;13(1):71-9.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr;13(2):185-92.
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Fan L, Liedke PE, Isakoff SJ, St Louis J, Ryan PD, Goss PE. Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review. Clin Breast Cancer. 2014 Apr;14(2):e41-5.
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute. 2008 Sep 03;100(17):1204-14.   PMCID: PMC2528020
Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Statistics in medicine. 2007 Oct 30;26(24):4400-15.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Phase II Clinical Trials as Topic

Phase II Clinical Trials as Topic drug therapy therapeutic use pathology methods Female Middle Aged metabolism Randomized Controlled Trials as Topic Aged Salvage Therapy Antineoplastic Agents Urologic Neoplasms Treatment Outcome Time Factors Disease-Free Survival Prognosis Male Antineoplastic Combined Chemotherapy Protocols Survival Analysis mortality Prospective Studies Neoplasm Staging Neoadjuvant Therapy drug effects Cohort Studies Breast Neoplasms Perioperative Care Neoplasm Metastasis Neoplasms Estrogen Receptors Research Design Phase III Clinical Trials as Topic Urothelium Clinical Trials as Topic Adult Monoclonal Antibodies Urinary Bladder Neoplasms Sirolimus Biological Products Sample Size Disease resistance TOR Serine-Threonine Kinases 3-Ring Heterocyclic Compounds Organoplatinum Compounds Review Literature as Topic Drug Therapy statistics & numerical data adverse effects Cell Survival Partial response Retrospective Studies Sulfones Salvage systemic therapy Proto-Oncogene Proteins c-akt Triazoles Number of prior regimens United States Ovarian Neoplasms Cyclooxygenase 2 Inhibitors Discontinuous therapy Advanced urothelial carcinoma Adjuvant Chemotherapy enzymology Cyclooxygenase 2 Nitriles Urothelial carcinoma Risk Factors United States Food and Drug Administration Disease Progression Aromatase inhibitor Patient Selection pharmacokinetics Neoplasm Invasiveness standards 80 and over Aged Cisplatin Biological Tumor Markers Notch Receptors secondary Drug Approval Transitional Cell Carcinoma Complete response Hormone-Dependent Neoplasms IGF Type 1 Receptor Aromatase Inhibitors Statistical Models Salvage therapy antagonists & inhibitors Carcinoma Multicenter Studies as Topic Tissue Distribution Prior perioperative chemotherapy Proportional Hazards Models Tumor Biomarkers Propionates Benzene Derivatives Tumor Cell Line Prostatic Neoplasms Follow-Up Studies Celecoxib therapy analogs & derivatives Progression-free survival Overall survival Progression-Free Survival Regression Analysis Advanced
Last updated on Wednesday, March 04, 2020